UNLABELLED: Drug interactions are important potential causes of adverse drug reactions. However, studies of their occurrence in children are almost entirely lacking. This study evaluates the incidence of potential drug interactions (PDIs) in medication prescriptions for children. The study was performed at the University Hospital in Olomouc. PDIs in each patient's prescriptions were identified. Multivariate analysis was performed in order to assess the risk factors confounding the potential interactions. Univariate analysis was used to assess which diagnostic groups and medication groups significantly increase or lower the odds of a potential drug-drug interaction. A total of 6,078 patients meeting the inclusion criteria entered the study. They received 19,522 prescriptions. PDIs were identified in 3.83 % of patients (moderate-to-severe cases in 0.47 %). Patient age (p = 0.008), the average number of prescriptions per visit (p < 0.0001), and the number of visits per year (p < 0.0001) were found to increase the risk of drug interaction. The presence of epilepsy, leukemia, or rheumatoid arthritis and related disease diagnoses were discovered to increase the risk of PDIs significantly. CONCLUSION: The risk of PDIs in children is low, but it increases significantly with age and the number of drugs prescribed, particularly antiepileptics and immunosuppressants. The finding of a potential interaction in 0.47 % of all children in whom any medication was prescribed should not be underestimated since it means a significant risk for one child out of every 200, and it is also substantially higher in the chronically ill. Pediatricians should be aware of relevant interactions and should prevent them by therapeutic drug monitoring or appropriate clinical and laboratory monitoring.

Department of Pharmacology Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc Hnevotinska 3 77515 Olomouc Czech Republic

Zobrazit více v PubMed

Expert Rev Clin Pharmacol. 2011 Nov;4(6):743-50 PubMed

Curr Drug Saf. 2011 Feb 1;6(1):23-9 PubMed

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):221-9 PubMed

J Clin Pharmacol. 2011 Jul;51(7):1043-50 PubMed

Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):641-51 PubMed

Drugs Aging. 2010 Sep 1;27(9):759-70 PubMed

Curr Neuropharmacol. 2010 Sep;8(3):254-67 PubMed

Paediatr Drugs. 2009;11(4):251-7 PubMed

Drugs. 1993;46 Suppl 1:83-90 PubMed

Pharmacotherapy. 1998 Sep-Oct;18(5):1112-20 PubMed

Pharm World Sci. 2010 Dec;32(6):815-21 PubMed

Drug Saf. 1993 Jul;9(1):51-9 PubMed

World J Gastroenterol. 2010 Dec 7;16(45):5651-61 PubMed

Aliment Pharmacol Ther. 2008 Nov 1;28(9):1021-41 PubMed

J Clin Pharm Ther. 2005 Feb;30(1):13-20 PubMed

J Pediatr. 2008 Apr;152(4):521-6, 526.e1-4 PubMed

J Pharm Pharm Sci. 2009;12(3):266-72 PubMed

J Pediatr. 2003 May;142(5):572-4 PubMed

Eur J Clin Pharmacol. 2003 Mar;58(11):773-8 PubMed